Skip to main content
Erschienen in: BMC Pulmonary Medicine 1/2009

Open Access 01.12.2009 | Research article

Effects of acute hypoventilation and hyperventilation on exhaled carbon monoxide measurement in healthy volunteers

verfasst von: Franco Cavaliere, Carmen Volpe, Riccardo Gargaruti, Andrea Poscia, Michele Di Donato, Giovanni Grieco, Umberto Moscato

Erschienen in: BMC Pulmonary Medicine | Ausgabe 1/2009

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Background

High levels of exhaled carbon monoxide (eCO) are a marker of airway or lung inflammation. We investigated whether hypo- or hyperventilation can affect measured values.

Methods

Ten healthy volunteers were trained to achieve sustained end-tidal CO2 (etCO2) concentrations of 30 (hyperventilation), 40 (normoventilation), and 50 mmHg (hypoventilation). As soon as target etCO2 values were achieved for 120 sec, exhaled breath was analyzed for eCO with a photoacoustic spectrometer. At etCO2 values of 30 and 40 mmHg exhaled breath was sampled both after a deep inspiration and after a normal one. All measurements were performed in two different environmental conditions: A) ambient CO concentration = 0.8 ppm and B) ambient CO concentration = 1.7 ppm.

Results

During normoventilation, eCO mean (standard deviation) was 11.5 (0.8) ppm; it decreased to 10.3 (0.8) ppm during hyperventilation (p < 0.01) and increased to 11.9 (0.8) ppm during hypoventilation (p < 0.01). eCO changes were less pronounced than the correspondent etCO2 changes (hyperventilation: 10% Vs 25% decrease; hypoventilation 3% Vs 25% increase). Taking a deep inspiration before breath sampling was associated with lower eCO values (p < 0.01), while environmental CO levels did not affect eCO measurement.

Conclusions

eCO measurements should not be performed during marked acute hyperventilation, like that induced in this study, but the influence of less pronounced hyperventilation or of hypoventilation is probably negligible in clinical practice
Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1471-2466-9-51) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

FC and UM conceived of the study and reviewed the manuscript. RG and MDD were involved with data collection and statistical analysis. CV, GG, and AP drafted the manuscript.
All authors read and approved the final manuscript.

Background

In the human body, carbon monoxide (CO) has two origins: the exogenous source is the absorption from tobacco smoke and polluted air, the endogenous one is the breakdown of heme molecules by heme oxidase (HO) [1, 2]. Exogenous CO increases in relation with the exposure to tobacco smoke and polluted air. Endogenous CO grows in the case of increased heme catabolism, caused by hemolysis, or by the synthesis of the isoenzyme HO-1, also known as stress-inducible heat shock protein 32, which is upregulated by a variety of stressors, such as cytokines, hypoxia, and reactive oxygen species. In all cases, the increased CO in the body results in increased CO levels in exhaled breath (eCO). Consequently eCO measurements may be useful to evaluate smoking abstinence [3], exposition to polluted air [4], oxidative stress caused by anaesthesia or surgery [5], severe sepsis [6], stable asthma and asthma exacerbations [7, 8], chronic obstructive pulmonary disease (COPD) [9], hemolysis in children with sickle cell disease [10], and upper [11] and lower airway inflammation [12]. Table 1 reports some examples of eCO levels in smoking healthy subjects and patients with significant issues.
Table 1
Exhaled CO levels in smoking healthy subjects and patients with significant issues.
Authors
Diseases or smoking
Exhaled CO level (ppm)
N. Subjects
  
Mean
Range or S.D. or 95% C.I.
 
Deveci et al (2004) [27]
Smoking
17.13
± 8.5
243
Carpagnano et al (2003)[28]
Smoking
16.70
± 5.5
31
Montuschi et al. (2001) [9]
COPD
7.40
± 1.9
15
Montuschi et al. (2001) [9]
COPD + Smoking
20.0
± 2.6
15
Biernacki et al (2001) [12]
LRTI
5.20
± 0.5
35
Yamaya et al (1998) [29]
URTI
5.60
± 0.4
20
Ohara Y et al (2006) [7]
Asthma
5.10
± 0.4
22
Kiyoshi et al (1997) [30]
Asthma
5.60
± 0.6
12
Paredi et al (1999) [31]
CF
6.70
± 0.6
29
Horvath et al. (2003) [32]
Bronchiectasis
5.00
3.0 - 15.0
31
De Las Heras et al (2003) [33]
SBP
7.00
± 0.5
9
COPD chronic obstructive pulmonary disease; LRTI lower respiratory tract infection; URTI upper respiratory tract infections; CF cystic fibrosis; SBP spontaneous bacterial peritonitis;
Independently from the amount of CO produced by a patient, his/her eCO levels may be influenced by the condition in which measurements are performed. For instance eCO can temporarily increase during oxygen therapy because hyperoxia facilitates CO release from carboxyhemoglobin [1315]. Acute hyperventilation may decrease eCO values by dilution; in addition theoretical models suggest that alveolar ventilation may affect CO stores by varying the partial pressure of this gas in the alveoli and consequently in blood and tissues. In that case a proportionate amount of CO should be released or stored in order to achieve a new equilibrium [16]. This process can take several hours, meanwhile eCO measures may be poorly representative of CO production.
Changes of ventilatory pattern can potentially occur near eCO measurements. Patients can be induced to hyperventilate by the procedure of breath sampling itself [17]; furthermore, acute ventilatory changes are not infrequent in asthma exacerbations, sepsis, or during assisted mechanical ventilation. The aim of this study was to evaluate whether acute hypo- or hyperventilation can affect eCO measurements. Secondarily, we evaluated the influence of environmental CO and breath sampling procedure on eCO measurements.

Methods

The study was carried out in the Catholic University of the Sacred Heart in Rome. Measurements were performed in duplicate in two laboratories situated in different buildings, the first one in the Surgical Intensive Care Unit (A), the second in the institute of Hygiene (B). After the approval of local Ethic Committee and informed consent, 10 healthy volunteers (5 men and 5 women) were enrolled in the study. Table 2 reports theirs anthropometric and lung functions values.
Table 2
Anthropometric and lung function values as means (standard deviations) of the healthy volunteers enrolled in this study.
 
Men
Women
AGE (anni)
31.40 (12.30)
28.60 (12.20)
BMI (Kg/m 2 )
24.19 (1.41)
20.88 (3.10)
FEV 1 (L)
3.76 (0.40)
2,62 (0.64)
FVC (L)
4.23 (0.48)
3.02 (0.67)
FEV 1 /FVC (%)
88.95 (1.85)
86.57 (2.10)
PFER (L/s)
8.57(0.96)
5.32 (1.33)
BMI body mass index; FEV1 forced expiratory volume in one second; FVC forced vital capacity; FEV1/FVC forced expiratory volume in one second/forced vital capacity; PEFR peak expiratory flow rate;
Exclusion criteria were: a) active or passive tobacco smoke, b) chronic respiratory diseases, and c) acute respiratory diseases occurred in the past four months.
In each subject, eCO was measured at end tidal CO2 (etCO2) values of 30, 40, and 50 mmHg in A and B settings. At etCO2 values of 30 and 40 mmHg, exhaled gases were collected both after normal inspiration and after maximum inspiration. Measurements at 50 mmHg were only performed after normal inspiration in order to avoid a brisk etCO2 decrease. Measurement were performed twice in each setting.
Subjects were asked to breath through a mouth piece in a device (figure 1) including a) a HME bacterial/viral filter (DAR Barrierbac S, Mallinkrodt DAR, Italy); b) the cell of the main stream capnometer CosmoPlus mod. 8100 (Novametrix Medical Systems Inc. Connecticut, USA) in order to measure etCO2; c) a tracheal tube (Mallinkrodt Inc, UK) with an internal diameter of 9 mm in order to prevent any risk of collecting external air during sampling for eCO measurements. The HME filter (internal volume 35 mL) protected the capnometer cell from condensation and allowed gas sampling for eCO measurements from the capnometry port. Initially, subjects were trained: a) to perform a prolonged expiration that lasted not less than 16 seconds, and b) to hypoventilate or hyperventilate in order to maintain a target etCO2 value on the display of the capnometer. Successively, they were asked to achieve the etCO2 values of 30, 40, and 50 mmHg in random sequence. As soon as the target etCO2 value was maintained within a range of ± 2 mmHg for 120 sec, the patients were asked to perform a prolonged expiration and exhaled gases were sampled for eCO analysis.
Breath samples were suctioned through a tube 1 m long and with an internal diameter of 3 mm by the photoacoustic spectrometer utilized for CO analysis; 80 mL were collected in 10 sec. Sampling was started by an operator three seconds after the beginning of a prolonged expiration lasting 16 seconds or more. It was initially assessed with capnography that an interval of two seconds was long enough to avoid anatomical dead space sampling. As a further precaution, the operator looked at the capnogram displayed by Cosmo plus during gas sampling; if sampling started before phase C (alveolar plateau), the procedure was repeated. The etCO2 value measured before (pre-test etCO2) and during (test etCO2) each eCO measurements and the peripheral arterial oxygen saturation (SpO2) were registered. Before each session of the study, the capnometer was calibrated and environmental CO concentration was measured.
eCO was measured with a photo-acoustic spectrometer field gas monitor Innova 1312 (LumaSense Technologies A/S, Denmark) equipped with a filter for CO analysis and with the software 7300 (LumaSense Technologies A/S, Denmark). The instrument is based on the photo-acoustic effect in the infra-red wave-lenghts[18]. Sampled CO absorbs light energy at a specific wave length, emitted by spectrometer, and transforms it into kinetic energy; this process causes local heating and pressure waves resulting in sounds that can be detected by a microphone. The photo-acoustic field gas monitor suctions gaseous samples by a pump to fill the photo-acoustic cell in which measurements are performed. Dead space, water-vapor's (or other gases) and temperature interference were automatically compensated. Detection limit was ≥ 0.02 ppm (part per million), with Sample Integration Times (S.I.T.) fixed at 5 seconds and multiplication factor 1.
The statistical analysis was carried out with the software "Statistica for Windows" (StatSoft Inc, USA) and STATA Intercooled v. 9.2 software for MacIntosh (Stata Co.; College Station Lakewag, TX, USA). Values are reported as means (standard deviations). Major deviations from normal distribution were ruled out by graphic inspection and by Shapiro-Wilks's test. The Kruskal-Wallis (K-W) equality-of-populations rank test (adjusted with Bonferroni at level of significance p ≤ 0.05) was employed to assess real difference of variation between lab A vs lab B.
Statistical analysis on eCO values was performed with ANOVA for repeated measures; planned comparisons were tested with linear contrasts. Factors taken into account were setting (lab A Vs B) and etCO2 (30 Vs 40 Vs 50 mmHg); planned comparisons were hypoventilation Vs normoventilation, hyperventilation Vs normoventilation, normal inspirations Vs deep inspiration. ANOVA for repeated measures was also applied to SpO2 values. The factor taken into account was etCO2; planned comparisons were hypoventilation Vs normoventilation and hyperventilation Vs normoventilation. Finally, pre-test and test etCO2 values were compared with paired t-test.

Results

eCO analysis showed a good level of reproducibility. The mean difference between duplicate measurements was 0.11 (0.20) ppm. Environmental CO concentration was 0.8 ppm in lab A and 1.7 ppm in lab B.
eCO values are reported in table 3. In comparison with normoventilation, eCO values were lower during hyperventilation and higher during hypoventilation (p < 0.01 in both cases); difference was more pronounced between normo- and hyperventilation (mean value: 1.2 ppm) than between normo- and hypoventilation (mean value: 0.4 ppm). No significant difference was observed between measurements performed in lab A and B (K-W test), while measured eCO levels were significantly lower when gas sampling was performed after a deep inspiration than after a normal inspiration (p < 0.01).
Table 3
Exhaled carbon monoxide values registered in laboratory A and B.
Et-CO2 target
30 mmHg (hyperventilation)
40 mmHg (normoventilation)
50 mmHg (hypoventilation)
Inspiration
Normal
Deep
Normal
Deep
Normal
Lab A (0.8 ppm)
10.2(0.9)
9.6(0.8)
11.4(0.8)
10.7(0.8)
11.8(0.9)
Lab B (1.7 ppm)
10.3(0.7)
9.7(0.7)
11.6(0.8)
10.8(0.8)
11.9(0.7)
Total
10.3(0.8)
9.7(0.8)
11.5(0.8)
10.8(0.8)
11.9(0.8)
Means (standard deviations) of exhaled carbon monoxide (eCO) values registered in laboratory A and B (environmental eCO level 0.8 and 1.7 ppm, respectively). Values are reported as particles per milion (ppm) .
Statistical analysis: ANOVA: LabA Vs Lab B non significant; hyperventilation Vs normoventilation p < 0.01; hyperventilation Vs normoventilation p < 0.01; normal inspiration Vs deep inspiration p < 0.01.
Table 4 reports SpO2 and etCO2 values. In comparison with normoventilation, SpO2 increased during hyperventilation and decreased during hypoventilation (p < 0.01 in both cases). Test etCO2 registered during the prolonged expiration for gas sampling were significantly higher than pre-test etCO2 (p < 0.01).
Table 4
Exhaled carbon monoxide, end tidal CO2, and peripheral oxygen saturation.
Et-CO2 target
30 mmHg (hyperventilation)
40 mmHg (normoventilation)
50 mmHg (hypoventilation)
Inspiration
Normal
Deep
Normal
Deep
Normal
eCO (ppm)
10.3 (0.8)
9.7 (0.8)
11.5 (0.8)
10.8 (0.8)
11.9 (0.8)
Pre-test etCO 2 (mmHg)
29.4 (1.6)
28.7 (1.6)
39.4 (1.7)
39.2 (1.7)
49.1 (1.7)
Test etCO 2 (mmHg)
37.8 (2.5)
35.6 (2.8)
46.1 (3.3)
43.0 (2.9)
51.6 (3)
SpO 2 (%)
99 (1)
98 (1)
96 (2)
Means (standard deviations) of exhaled carbon monoxide (eCO) values, end tidal CO2 values measured before and during breath sampling (respectively pre-test etCO2 and test etCO2), and peripheral oxygen saturation (SpO2).
Statistical analysis. EtCO2: pre-test Vs test p < 0.01. SpO2: ANOVA p < 0.01; hyperventilation Vs normoventilation p < 0.01; hyperventilation Vs normoventilation p < 0.01.

Discussion

In general ventilation patterns can influence quantification of volatile analytes in exhaled breath and should be controlled to ensure representative analyses [17]. In this study we evaluated whether acute hypo- or hyperventilation can significantly influence eCO measurements. This hypothesis was only partially confirmed because hyperventilation decreased eCO, but to a much lesser extent than etCO2; in practice, eCO decreased by 10% while etCO2 decreased by 25%. Hypoventilation had an even lesser effect, causing a small and clinically negligible eCO increase (3%) while etCO2 increased by 25%. We also found that eCO measurements were not affected by environmental CO, but decreased slightly if a deep inspiration is taken before breath sampling.
Changes of ventilatory pattern are common in patients affected by respiratory diseases, particularly during mechanical ventilation; in addition, the procedure of breath sampling itself may induce patients to hyperventilate [17]. Acute hypo- and hyperventilation cause proportional changes of the levels of many analytes, such as CO2, isoprene, and ethane, in exhaled breath [1719]. By contrast our results point out that hypo- and hyperventilation have small impact on eCO measurements; this is in agreement with the observation reported by other Authors that ventilatory changes affects eCO and etCO2 differently [17].
Our results are apparently in contrast with theoretical predictions. In steady state, eCO is strictly correlated with the endogenous production of CO and with carboxyhaemoglobin blood levels [20], but these relationships are influenced by alveolar ventilation, as well as by the environmental CO levels, by the diffusing capacity of the lung for CO, and by the oxygen partial pressure in pulmonary capillaries [16]. By means of a mathematical model, Cobourn and Coll calculated that doubling alveolar ventilation from 4 to 8 liters per minute in a patient with a normal CO production of 0.42 mL per hour would have resulted in a 43% decrease of carboxyhaemoglobin, from 0.37 to 0.21% [16]; a corresponding variation can be hypothesized for eCO. The smaller changes observed in this study are possibly explained because calculations were referred to the new steady state that may be achieved only several hours after ventilatory variations. Cobourn and Coll estimated that the half-life of the process was about 7 hours [16], far longer than the half-life of CO2 store variations, which have been estimated around 70 minutes or less with animal models [21, 22] and around 35 minutes in men [19]. The longer CO half-life may be explained by the small amount of this gas released every minute through the lungs in comparison with the stores in the human body. Stored CO has been estimated at 10 mL, 8 of which are bound to hemoglobin [23]. The CO released by a healthy man is about 0.4 mL per hours [21] i.e. 7 μL per minute, which corresponds to about 0.07% of body stores and 0.09% of blood content. Conversely, the readily exchangeable CO2 stored in the body is about 14 L [24] and the CO2 released is about 200-250 mL per minute, which corresponds to about 1.4-1.8% of body stores. As a consequence the stabilization of eCO and blood carboxyhemoglobin levels after ventilatory changes requires many hours. Hypothetically, if in this study hypoventilation or hyperventilation had been prolonged for a time interval long enough to approximate the steady state, eCO changes would have possibly shown the same magnitude of etCO2changes.
Our results stress the importance of standardizing the procedure for measuring eCO. We observed that taking a deep or normal inspiration can affect eCO levels, other Authors reported that measuring after a breath hold may result in higher eCO values than sampling without breath hold [25] In addition, our data suggest that, even in healthy subjects, a deep expiration may recruit pulmonary alveoli that are poorly represented in a normal expiration since a significant difference was observed between etCO2 values measured immediately before (pre-test) and during (test) breath sampling. Of note, pulmonary heterogeneity strongly affects the relationship between eCO and CO-Hb, [16] which is lost in patients affected by severe pulmonary emphysema or airway obstruction [20, 26].
A limit of our study is that we did not evaluate the effects of prolonged ventilatory changes on eCO. In addition, we measured CO values by a photoacoustic spectrometer. To our knowledge this kind of instrument has not been utilized for eCO measurement before. In this study photoacoustic spectrometer performed CO analysis with very high sensitivity and precision on breath samples that were representative of the entire exhaled breath. Theoretically the eCO values obtained with our method may reflect a wider alveolar population in comparison with the end tidal values provided by electrochemical sensors that are utilized for routine eCO measurements. These methodological differences may partly explain why the volunteers enrolled in this study presented relatively high eCO values for non-smokers compared with literature data (Table 5). Other possible explanations were that all the subjects lived in densely populated urban environment and were consequently exposed to high levels of environmental CO and that eCO values are characterized by large interindividual variability [4]; as a matter of fact, eCO levels similar to those observed in this study have been reported in healthy non smokers by other authors [14].
Table 5
Exhaled carbon monoxide values in non smoking healthy subjects reported in literature.
Authors
Exhaled CO level (ppm)
N. Subjects
 
Mean
Range or S.D. or 95% C.I.
 
Chatkin J. et al. (2007) [3]
4.30
± 2.5
152
Cunnington and Hormbrey (2002) [34]
1.26
1.14-1.37
366
Deveci et al (2004) [27]
3.61
± 2.15
55
Horvath et al. (2003) [32]
3.00
0.5-5.0
37
Laranjeira R. at al (2000) [35]
2.50
1.0 - 4.0
100
Montuschi et al. (2001) [9]
3.00
± 0.3
10
Scharte et al. (2000) [36]
1.55
1.2-1.7
6

Conclusions

While eCO values are scarcely affected by hypoventilation that occurs during measurement, hyperventilation should be avoided because it significantly decreases eCO values. Nonetheless light hyperventilation occurring during measurements may be acceptable because eCO changes are much less pronounced than ventilation changes (reflected by etCO2).
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

FC and UM conceived of the study and reviewed the manuscript. RG and MDD were involved with data collection and statistical analysis. CV, GG, and AP drafted the manuscript.
All authors read and approved the final manuscript.
Anhänge

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.
Literatur
1.
Zurück zum Zitat Wu L, Wang R: Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev. 2005, 57 (4): 585-630. 10.1124/pr.57.4.3.CrossRefPubMed Wu L, Wang R: Carbon monoxide: endogenous production, physiological functions, and pharmacological applications. Pharmacol Rev. 2005, 57 (4): 585-630. 10.1124/pr.57.4.3.CrossRefPubMed
2.
Zurück zum Zitat Ryter SW, Alam J, Choi AM: Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006, 86 (2): 583-650. 10.1152/physrev.00011.2005.CrossRefPubMed Ryter SW, Alam J, Choi AM: Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol Rev. 2006, 86 (2): 583-650. 10.1152/physrev.00011.2005.CrossRefPubMed
3.
Zurück zum Zitat Chatkin J, Fritscher L, de Abreu C, Cavalet-Blanco D, Chatkin G: Exhaled carbon monoxide as a marker for evaluating smoking abstinence in a Brazilian population sample. Prim Care Respir J. 2007, 16 (1): 36-40. 10.3132/pcrj.2007.00008.CrossRefPubMed Chatkin J, Fritscher L, de Abreu C, Cavalet-Blanco D, Chatkin G: Exhaled carbon monoxide as a marker for evaluating smoking abstinence in a Brazilian population sample. Prim Care Respir J. 2007, 16 (1): 36-40. 10.3132/pcrj.2007.00008.CrossRefPubMed
4.
Zurück zum Zitat Jones AY, Lam PK: End-expiratory carbon monoxide levels in healthy subjects living in a densely populated urban environment. Sci Total Environ. 2006, 354 (2-3): 150-6. 10.1016/j.scitotenv.2005.02.018.CrossRefPubMed Jones AY, Lam PK: End-expiratory carbon monoxide levels in healthy subjects living in a densely populated urban environment. Sci Total Environ. 2006, 354 (2-3): 150-6. 10.1016/j.scitotenv.2005.02.018.CrossRefPubMed
5.
Zurück zum Zitat Hayashi M, Takahashi T, Morimatsu H, Fujii H, Taga N: Increased carbon monoxide concentration in exhaled air after surgery and anesthesia. Anesth Analg. 2004, 99 (2): 444-8. 10.1213/01.ANE.0000123821.51802.F3.CrossRefPubMed Hayashi M, Takahashi T, Morimatsu H, Fujii H, Taga N: Increased carbon monoxide concentration in exhaled air after surgery and anesthesia. Anesth Analg. 2004, 99 (2): 444-8. 10.1213/01.ANE.0000123821.51802.F3.CrossRefPubMed
6.
Zurück zum Zitat Zegdi R, Perrin D, Burdin M, Boiteau R, Tenaillon A: Increased endogenous carbon monoxide production in severe sepsis. Intensive Care Med. 2002, 28 (6): 793-6. 10.1007/s00134-002-1269-7.CrossRefPubMed Zegdi R, Perrin D, Burdin M, Boiteau R, Tenaillon A: Increased endogenous carbon monoxide production in severe sepsis. Intensive Care Med. 2002, 28 (6): 793-6. 10.1007/s00134-002-1269-7.CrossRefPubMed
7.
Zurück zum Zitat Ohara Y, Ohrui T, Morikawa T, He M, Yasuda : Exhaled carbon monoxide levels in school-age children with episodic asthma. Pediatr Pulmonol. 2006, 41 (5): 470-4. 10.1002/ppul.20395.CrossRefPubMed Ohara Y, Ohrui T, Morikawa T, He M, Yasuda : Exhaled carbon monoxide levels in school-age children with episodic asthma. Pediatr Pulmonol. 2006, 41 (5): 470-4. 10.1002/ppul.20395.CrossRefPubMed
8.
Zurück zum Zitat Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ: Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med. 1999, 160 (1): 216-20.CrossRefPubMed Montuschi P, Corradi M, Ciabattoni G, Nightingale J, Kharitonov SA, Barnes PJ: Increased 8-isoprostane, a marker of oxidative stress, in exhaled condensate of asthma patients. Am J Respir Crit Care Med. 1999, 160 (1): 216-20.CrossRefPubMed
9.
Zurück zum Zitat Montuschi P, Kharitonov SA, Barnes PJ: Exhaled carbon monoxide and nitric oxide in COPD. Chest. 2001, 120 (2): 496-501. 10.1378/chest.120.2.496.CrossRefPubMed Montuschi P, Kharitonov SA, Barnes PJ: Exhaled carbon monoxide and nitric oxide in COPD. Chest. 2001, 120 (2): 496-501. 10.1378/chest.120.2.496.CrossRefPubMed
10.
Zurück zum Zitat Sylvester KP, Patey RA, Rafferty GF, Rees D, Thein SL: Exhaled carbon monoxide levels in children with sickle cell disease. Eur J Pediatr. 2005, 164 (3): 162-5. 10.1007/s00431-004-1605-8.CrossRefPubMed Sylvester KP, Patey RA, Rafferty GF, Rees D, Thein SL: Exhaled carbon monoxide levels in children with sickle cell disease. Eur J Pediatr. 2005, 164 (3): 162-5. 10.1007/s00431-004-1605-8.CrossRefPubMed
11.
Zurück zum Zitat Andersson JA, Uddman R, Cardell LO: Increased carbon monoxide levels in the nasal airways of subjects with a history of seasonal allergic rhinitis and in patients with upper respiratory tract infection. Clin Exp Allergy. 2002, 32 (2): 224-7. 10.1046/j.1365-2222.2002.00532.x.CrossRefPubMed Andersson JA, Uddman R, Cardell LO: Increased carbon monoxide levels in the nasal airways of subjects with a history of seasonal allergic rhinitis and in patients with upper respiratory tract infection. Clin Exp Allergy. 2002, 32 (2): 224-7. 10.1046/j.1365-2222.2002.00532.x.CrossRefPubMed
12.
Zurück zum Zitat Biernacki WA, Kharitonov SA, Barnes PJ: Exhaled carbon monoxide in patients with lower respiratory tract infection. Respir Med. 2001, 95 (12): 1003-5. 10.1053/rmed.2001.1196.CrossRefPubMed Biernacki WA, Kharitonov SA, Barnes PJ: Exhaled carbon monoxide in patients with lower respiratory tract infection. Respir Med. 2001, 95 (12): 1003-5. 10.1053/rmed.2001.1196.CrossRefPubMed
13.
Zurück zum Zitat Zegdi R, Caid R, Louw Van De A, Perrin D, Burdin M: Exhaled carbon monoxide in mechanically ventilated critically ill patients: influence of inspired oxygen fraction. Intensive Care Med. 2000, 26 (9): 1228-31. 10.1007/s001340000590.CrossRefPubMed Zegdi R, Caid R, Louw Van De A, Perrin D, Burdin M: Exhaled carbon monoxide in mechanically ventilated critically ill patients: influence of inspired oxygen fraction. Intensive Care Med. 2000, 26 (9): 1228-31. 10.1007/s001340000590.CrossRefPubMed
14.
Zurück zum Zitat Schober P, Kalmanowicz M, Loer SA: Effects of inspiratory oxygen concentration on endtidal carbon monoxide concentration. J Clin Monit Comput. 2006, 20 (2): 89-94. 10.1007/s10877-006-9011-6.CrossRefPubMed Schober P, Kalmanowicz M, Loer SA: Effects of inspiratory oxygen concentration on endtidal carbon monoxide concentration. J Clin Monit Comput. 2006, 20 (2): 89-94. 10.1007/s10877-006-9011-6.CrossRefPubMed
15.
Zurück zum Zitat Adachi T, Hirota K, Hara T, Sasaki Y, Hara Y: Exhaled carbon monoxide levels change in relation to inspired oxygen fraction during general anesthesia. Anesth Analg. 2007, 105 (3): 696-9. 10.1213/01.ane.0000278118.60543.7a.CrossRefPubMed Adachi T, Hirota K, Hara T, Sasaki Y, Hara Y: Exhaled carbon monoxide levels change in relation to inspired oxygen fraction during general anesthesia. Anesth Analg. 2007, 105 (3): 696-9. 10.1213/01.ane.0000278118.60543.7a.CrossRefPubMed
16.
Zurück zum Zitat Coburn RF, Forster RE, Kane PB: Considerations of the physiological variables that determine the blood carboxyhaemoglobin concentration in man. J Clin Invest. 1965, 44: 1899-910. 10.1172/JCI105296.CrossRefPubMedPubMedCentral Coburn RF, Forster RE, Kane PB: Considerations of the physiological variables that determine the blood carboxyhaemoglobin concentration in man. J Clin Invest. 1965, 44: 1899-910. 10.1172/JCI105296.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Cope KA, Watson MT, Foster M, Sehnert SS, Risby TH: Effects of ventilation on the collection of exhaled breath in humans. J Appl Physiol. 2004, 96 (4): 1371-9. 10.1152/japplphysiol.01034.2003.CrossRefPubMed Cope KA, Watson MT, Foster M, Sehnert SS, Risby TH: Effects of ventilation on the collection of exhaled breath in humans. J Appl Physiol. 2004, 96 (4): 1371-9. 10.1152/japplphysiol.01034.2003.CrossRefPubMed
18.
Zurück zum Zitat Harren FJM, Cotti G, Oomens J, Lintel Hekkert S: Photoacoustic spectroscopy in trace gas monitoring. Encyclopedia of Analytical Chemistry. 2000, John Wiley & Sons Ltd. Chichester, 2203-26. [RA Meyers (Series Editor)] Harren FJM, Cotti G, Oomens J, Lintel Hekkert S: Photoacoustic spectroscopy in trace gas monitoring. Encyclopedia of Analytical Chemistry. 2000, John Wiley & Sons Ltd. Chichester, 2203-26. [RA Meyers (Series Editor)]
19.
Zurück zum Zitat Taskar V, John J, Larsson A, Wetterberg T, Jonson B: Dynamics of carbon dioxide elimination following ventilator resetting. Chest. 1995, 108 (1): 196-202. 10.1378/chest.108.1.196.CrossRefPubMed Taskar V, John J, Larsson A, Wetterberg T, Jonson B: Dynamics of carbon dioxide elimination following ventilator resetting. Chest. 1995, 108 (1): 196-202. 10.1378/chest.108.1.196.CrossRefPubMed
20.
Zurück zum Zitat Jarvis MJ, Belcher M, Vesey C, Hutchison DCS: Low cost carbon monoxide monitors in smoking assessment. Thorax. 1986, 41 (11): 886-7. 10.1136/thx.41.11.886.CrossRefPubMedPubMedCentral Jarvis MJ, Belcher M, Vesey C, Hutchison DCS: Low cost carbon monoxide monitors in smoking assessment. Thorax. 1986, 41 (11): 886-7. 10.1136/thx.41.11.886.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Khambatta HJ, Sullivan SF: Carbon dioxide production and washout during passive hyperventilation alkalosis. J Appl Physiol. 1974, 37 (5): 665-9.PubMed Khambatta HJ, Sullivan SF: Carbon dioxide production and washout during passive hyperventilation alkalosis. J Appl Physiol. 1974, 37 (5): 665-9.PubMed
22.
Zurück zum Zitat Mohan OE, Cooper DM, Jensen SC, Armon Y, Landaw EM: CO2 washout kinetics in acute hypercapnia. Respir Physiol. 1991, 86 (2): 159-70. 10.1016/0034-5687(91)90078-W.CrossRefPubMed Mohan OE, Cooper DM, Jensen SC, Armon Y, Landaw EM: CO2 washout kinetics in acute hypercapnia. Respir Physiol. 1991, 86 (2): 159-70. 10.1016/0034-5687(91)90078-W.CrossRefPubMed
23.
Zurück zum Zitat Coburn RF: The carbon monoxide body stores. Ann NY Acad Sci. 1970, 174 (1): 11-22. 10.1111/j.1749-6632.1970.tb49768.x.CrossRefPubMed Coburn RF: The carbon monoxide body stores. Ann NY Acad Sci. 1970, 174 (1): 11-22. 10.1111/j.1749-6632.1970.tb49768.x.CrossRefPubMed
24.
Zurück zum Zitat Fowle AS, Matthews CM, Campbell EJ: The rapid distribution of H2O and CO2 in the body in relation to the immediate carbon dioxide storage capacity. Clin Sci. 1964, 27: 51-65.PubMed Fowle AS, Matthews CM, Campbell EJ: The rapid distribution of H2O and CO2 in the body in relation to the immediate carbon dioxide storage capacity. Clin Sci. 1964, 27: 51-65.PubMed
25.
Zurück zum Zitat Zetterquist W, Marteus H, Johannesson M, Nordval SL, Ihre E: Exhaled carbon monoxide is not elevated in patients with asthma or cystic fibrosis. Eur Respir J. 2002, 20 (1): 92-9. 10.1183/09031936.02.00245302.CrossRefPubMed Zetterquist W, Marteus H, Johannesson M, Nordval SL, Ihre E: Exhaled carbon monoxide is not elevated in patients with asthma or cystic fibrosis. Eur Respir J. 2002, 20 (1): 92-9. 10.1183/09031936.02.00245302.CrossRefPubMed
26.
Zurück zum Zitat Togores B, Bosch M, Agustí AGN: The measurement of exhaled carbon monoxide is influenced by airway obstruction. Eur Resp J. 2000, 15 (1): 177-80. 10.1183/09031936.00.15117700.CrossRef Togores B, Bosch M, Agustí AGN: The measurement of exhaled carbon monoxide is influenced by airway obstruction. Eur Resp J. 2000, 15 (1): 177-80. 10.1183/09031936.00.15117700.CrossRef
27.
Zurück zum Zitat Deveci SE, Deveci F, Açik Y, Ozan AT: The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir Med. 2004, 98 (6): 551-6. 10.1016/j.rmed.2003.11.018.CrossRefPubMed Deveci SE, Deveci F, Açik Y, Ozan AT: The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir Med. 2004, 98 (6): 551-6. 10.1016/j.rmed.2003.11.018.CrossRefPubMed
28.
Zurück zum Zitat Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Barnes PJ: Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J. 2003, 21 (4): 589-93. 10.1183/09031936.03.00022203.CrossRefPubMed Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, Resta O, Barnes PJ: Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur Respir J. 2003, 21 (4): 589-93. 10.1183/09031936.03.00022203.CrossRefPubMed
29.
Zurück zum Zitat Yamaya M, Sekizawa K, Ishizuka S, Monma M, Mizuta K, Sasaki H: Increased Carbon Monoxide in Exhaled Air of Subjects with Upper Respiratory Tract Infections. Am J Respir Crit Care Med. 1998, 158: 311-314.CrossRefPubMed Yamaya M, Sekizawa K, Ishizuka S, Monma M, Mizuta K, Sasaki H: Increased Carbon Monoxide in Exhaled Air of Subjects with Upper Respiratory Tract Infections. Am J Respir Crit Care Med. 1998, 158: 311-314.CrossRefPubMed
30.
Zurück zum Zitat Zayasu K, Sekizawa K, Okinaga S, Yamaya M, Ohrui T, Sasaki H: Increased Carbon Monoxide in Exhaled Air of Asthmatic Patients. Am J Respir Crit Care Med. 1997, 156: 1140-1143.CrossRefPubMed Zayasu K, Sekizawa K, Okinaga S, Yamaya M, Ohrui T, Sasaki H: Increased Carbon Monoxide in Exhaled Air of Asthmatic Patients. Am J Respir Crit Care Med. 1997, 156: 1140-1143.CrossRefPubMed
31.
Zurück zum Zitat Paredi P, Shah PL, Montuschi P, Sullivan P, Hodson ME, Kharitonov SA, Barnes PJ: Increased carbon monoxide in exhaled air of patients with cystic fibrosis. Thorax. 1999, 54: 917-920. 10.1136/thx.54.10.917.CrossRefPubMedPubMedCentral Paredi P, Shah PL, Montuschi P, Sullivan P, Hodson ME, Kharitonov SA, Barnes PJ: Increased carbon monoxide in exhaled air of patients with cystic fibrosis. Thorax. 1999, 54: 917-920. 10.1136/thx.54.10.917.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Horváth I, Loukides S, Wodehouse T, Csiszér E, Cole PJ, Kharitonov SA, Barnes PJ: Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax. 2003, 58 (1): 68-72. 10.1136/thorax.58.1.68.CrossRefPubMedPubMedCentral Horváth I, Loukides S, Wodehouse T, Csiszér E, Cole PJ, Kharitonov SA, Barnes PJ: Comparison of exhaled and nasal nitric oxide and exhaled carbon monoxide levels in bronchiectatic patients with and without primary ciliary dyskinesia. Thorax. 2003, 58 (1): 68-72. 10.1136/thorax.58.1.68.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat De las Heras D, Fernández J, Ginès P, Cárdenas A, Ortega R, Navasa M, Barberá JA, Calahorra B, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J: Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology. 2003, 38 (2): 452-9. 10.1053/jhep.2003.50304.CrossRefPubMed De las Heras D, Fernández J, Ginès P, Cárdenas A, Ortega R, Navasa M, Barberá JA, Calahorra B, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J: Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology. 2003, 38 (2): 452-9. 10.1053/jhep.2003.50304.CrossRefPubMed
34.
Zurück zum Zitat Cunnington AJ, Hormbrey P: Breath analysis to detect recent exposure to carbon monoxide. Postgrad Med J. 2002, 78 (918): 233-7. 10.1136/pmj.78.918.233.CrossRefPubMedPubMedCentral Cunnington AJ, Hormbrey P: Breath analysis to detect recent exposure to carbon monoxide. Postgrad Med J. 2002, 78 (918): 233-7. 10.1136/pmj.78.918.233.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Laranjeira R, Pillon S, Dunn J: Environmental tobacco smoke exposure among nonsmoking waiters: measurement of expired carbon monoxide levels. Sao Paulo Med J. 2000, 118 (4): 89-92. 10.1590/S1516-31802000000400003.CrossRefPubMed Laranjeira R, Pillon S, Dunn J: Environmental tobacco smoke exposure among nonsmoking waiters: measurement of expired carbon monoxide levels. Sao Paulo Med J. 2000, 118 (4): 89-92. 10.1590/S1516-31802000000400003.CrossRefPubMed
36.
Zurück zum Zitat Scharte M, Bone HG, Van Aken H, Meyer J: Increased carbon monoxide in exhaled air of critically ill patients. Biochem Biophys Res Commun. 2000, 267 (1): 423-6. 10.1006/bbrc.1999.1936.CrossRefPubMed Scharte M, Bone HG, Van Aken H, Meyer J: Increased carbon monoxide in exhaled air of critically ill patients. Biochem Biophys Res Commun. 2000, 267 (1): 423-6. 10.1006/bbrc.1999.1936.CrossRefPubMed
Metadaten
Titel
Effects of acute hypoventilation and hyperventilation on exhaled carbon monoxide measurement in healthy volunteers
verfasst von
Franco Cavaliere
Carmen Volpe
Riccardo Gargaruti
Andrea Poscia
Michele Di Donato
Giovanni Grieco
Umberto Moscato
Publikationsdatum
01.12.2009
Verlag
BioMed Central
Erschienen in
BMC Pulmonary Medicine / Ausgabe 1/2009
Elektronische ISSN: 1471-2466
DOI
https://doi.org/10.1186/1471-2466-9-51

Weitere Artikel der Ausgabe 1/2009

BMC Pulmonary Medicine 1/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.